Introduction
Natural killer (NK)/T cell lymphoma usually shows a highly aggressive clinical course and is much more common in Asian and Latin American countries than in Western countries (1) . The overall prognosis of this disease is poor due to frequent relapse or resistance to treatment (2, 3) . The response of NK/T cell lymphoma to combined radiotherapy and chemotherapy is usually frustratingly inadequate (4) . What is more, most patients initially have low International Prognostic Index (IPI) scores, as they usually present with localized disease involving the head and neck with good performance status (5, 6) .
Although the treatment of NK/T cell lymphoma has improved greatly, there are no standard therapeutic regimens for this disease. L-asparaginase (L-Asp) and pegaspargase (PEGAsp) are important chemotherapeutic drugs for childhood acute lymphoblastic leukemia (ALL), and clinical trials have also shown that L-Asp treatment improves the outcome of NK/T cell lymphoma (7) . The exact molecular events that cause cell death following L-Asp treatment remain unknown. However, suppression of protein synthesis is an obvious potential target and it has been documented that L-Asp exposure initiates the apoptosis of cells (8) . Although the chemotherapeutic protocols containing L-Asp have improved the efficacy of treatment, a number of patients are resistant to L-Asp or PEG-Asp, leading to treatment failure and poor long-term prognosis.
The asparagine synthetase (ASNS) gene encodes the enzyme that catalyzes the biosynthesis of asparagine from aspartate. This reaction proceeds in an ATP-dependent manner with glutamine serving as the nitrogen source (9) . Most tissues contain sufficient ASNS activity to maintain asparagine or the enzyme is upregulated in response to asparagine depletion (10, 11) . It was reported that primary ALL cells and many ALL cell lines exhibit a particularly low level of ASNS expression (12, 13) , and therefore, are unusually sensitive to asparagine depletion. Early studies demonstrated that the elevated expression of ASNS was correlated with the resistance of leukemic cells to L-Asp (14, 15) . Similarly, the expression and the functional significance of ASNS have been investigated in solid tumors. ASNS was considered as a causal, predictive biomarker for L-Asp activity in ovarian cancer cells (16, 17) . Furthermore, one study also showed that the enhanced expression of ASNS protected pancreatic cancer cells from apoptosis induced by glucose deprivation and cisplatin (18) . Recently, some studies found that ASNS is overexpressed in castration-resistant prostate cancer (CRPC) and that depletion of asparagine using ASNS inhibitors may be a novel strategy for targeting CRPC cells (19) . Another study showed that the expression of ASNS was an independent factor affecting the survival of HCC patients, and low ASNS expression in HCC was correlated with worse surgical outcomes (20) .
However, the expression and the functional roles of ASNS in lymphomas remain unclear, particularly in NK/T cell lymphoma. The significance of the expression level of ASNS in the prognosis of NK/T cell lymphoma patients who undergo chemotherapy containing L-Asp or PEG-Asp has not been reported. Therefore, it is meaningful to identify the level of ASNS expression and investigate its clinical significance in the development of NK/T cell lymphoma.
Materials and methods
Cell culture. Seven lymphoma cell lines (DOHH2, Hut-78, Jurkat, Karpas 299, Raji, SNK-6 and YTS) were stored in the Lymphoma Diagnosis and Treatment Center of Henan Province in the First Affiliated Hospital. All the cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) at 37˚C in an atmosphere of 5% CO 2 .
Cell proliferation assays. The effect of PEG-Asp on cell growth was determined by measuring 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma) absorbance in living cells. In brief, 1.0x0 5 cells/well were seeded in 96-well microtiter plates. Following exposure to the designated doses of PEG-Asp for the indicated times, MTT solution [20 µl: 2 mg/ml in phosphate-buffered saline (PBS)] was added to each well of 96-well plates. The plates were additionally incubated for 4 h at 37˚C. Medium was withdrawn from the plates by pipetting, and 200 µl DMSO was added to each well to solubilize the formazan crystals. The absorbance was recorded using a Teacan 96-well spectrophotometer at a wavelength of 570 nm.
Quantitative real-time PCR. Cell suspensions of DOHH2, Hut-78, Jurkat, Karpas 299, Raji, SNK-6 and YTS cells (the number of cells were 5x10 6 ) were collected, and the concentration of PEG-Asp at IC 50 was used to treat each cell line for 48 h. Total RNAs of the 7 lymphoma cell lines before and after drug treatment were then extracted respectively, and each RNA sample (3 µg) was subjected to cDNA synthesis by means of an RNA transcription kit (Thermo Fisher Scientific). Quantitative real-time PCR was performed using the Quantitative SYBR-Green PCR kit (Thermo Fisher Scientific) on the ABI PRISM 7500 Fast system (Applied Biosystems). All experiments were performed as specified according to the manufacturer's protocols. The primers used were as follows: ASNS forward, CTGCACGCCCTCTATGACA and reverse, TAAAAGGCAGCCAATCCTTCT; GAPDH forward, GAA GGTGAAGGTCGGAGTC and reverse, GAAGATGGTGAT GGGATTTC. All samples were analyzed using 3 parallel samples and repeated at least 3 times. The relative expression of the target gene was calculated using 2 Tumor staging was performed according to the Improved Ann Arbor installments. Physical condition scoring criteria used Zubrod-ECOG-WHO (ZPS, 5-point method). The patients who were further subjected to survival analysis had not undergone any previous treatment for lymphoma and received at least one of the following therapies: chemotherapy containing L-Asp (10,000 U/day for days 1-7 every cycle) or PEG-Asp (4,750 U every cycle) for at least 2 cycles. Paraffin-embedded tumor tissues were available for the patients. Tumor responses were assessed for every two cycles of chemotherapy. Complete response (CR) was defined according to the Revised Response Criteria for Lymphoma (22) . The follow-up period was defined as the interval from the date of diagnosis to the date of death or the last follow-up. Patients who died from other causes were treated as censored cases. All patients were observed until July 2013. Overall survival was defined as the interval between the date of diagnosis and death. Progression-free survival (PFS) was defined as the interval between the date of diagnosis and recurrence or progression; if recurrence was not diagnosed, patients were censored at the date of death or the last follow-up. This study was approved by the Ethics Committee of The First Affiliated Hospital of Zhengzhou University and informed consent was obtained from all participants according to the committee's regulations.
Branched DNA-liquidchip technology (bDNA-LCT)
. bDNA-LCT of SurExam Bio-Tech Co., Ltd. (Guangzhou, China) was used to detect the ASNS mRNA expression levels in the NK/T cell lymphoma tissues. The paraffin-embedded tissue samples of the patients were lysed. The samples then released the RNA, and the spherical particles in the kit further captured the target RNA. RNA signals were then amplified, and the Luminex system was used to detect the expression of the target mRNA level. The original data obtained by the Multi-Flow Fluorescence Luminex 200™ matrix was detected and uniformly processed. The result was the netMFI ASNS mRNA relative expression. Based on the median value, the patients were divided accrording to ASNS mRNA expression: the 'high expression group' and the 'low expression group'.
Statistical analysis. All data were processed by SPSS 16.0 software. The experimental data are expressed as mean ± standard deviation (mean ± SD). Mean values were considered significantly different at P≤0.05. Pearson's χ 2 test or Fisher's exact test was used to analyze the relationship between ASNS expression and the clinicopathological features. Survival curves were calculated using the Kaplan-Meier method and compared using the log-rank test. The Cox proportional-hazard regression model was used for analyses to explore the effect of the clinicopathological variables and ASNS expression on survival, and P≤0.05 was considered to indicate a statistically significant result.
Results
Cell proliferation assays. The MTT assay results showed that the sensitivity of the different lymphoma cell lines to PEG-Asp (for 48 h) varied greatly. YTS cells were the most sensitive to the treatment, DOHH2, Raji and SNK-6 cells were relatively more sensitive and Hut-78, Jurkat and Karpas 299 cells were naturally resistant to the treatment. The IC 50 values could not be determined for concentrations >150 U/ml. The IC 50 values of 4 cell lines are shown in Table I and Fig. 1 .
Comparison of ASNS expression in the lymphoma cell lines before and after treatment with PEG-Asp. Seven cell lines
were treated with PEG-Asp with concentrations at IC 50 for 48 h. Hut-78, Jurkat and Karpas 299 cells were naturally resistant to treatment at a concentration of 150 U/ml PEG-Asp. The expression levels and the differences in expression level of ASNS before and after PEG-Asp treatment are shown in Table II (Fig. 4) .
Association between ASNS expression and clinicopathological features.
We next examined the relationship between the ASNS expression levels in tumor tissues and the clinicopathological characteristics of 50 patients (Table III) 
Lack of correlation between ASNS expression level and CR rate.
The tumor responses to treatment were assessed for all of the patients who used the chemotherapy regimens containing L-Asp or PEG-Asp by imaging studies based on the International Standard Response criteria for non-Hodgkin's lymphoma. Comparing patients in the high and low ASNS groups, no significant difference was found in the response rate (P=0.393). These four individual parameters were further subjected to multivariate Cox proportional hazards model, which demonstrated that LDH (P=0.002), efficacy of primary therapy (P<0.001) and ASNS expression level (P=0.023) were also identified as independent prognostic factors for OS (Table IV) .
Association of the ASNS expression level with prognosis.

ASNS expression -----------------------------
Discussion
In the present study, we demonstrated for the first time the expression patterns and prognostic value of ASNS mRNA in NK/T cell lymphoma, including cell lines and clinical samples. We also demonstrated the downregulation of ASNS at the mRNA level in the NK/T cell lymphoma tissues when compared with the levels in chronic rhinitis and nasal polyps using bDNA-LCT. Our findings showed that expression of ASNS was linked strongly with the sensitivity to L-Asp and PEG-Asp treatment and to prognostic factors, including III-IV stage, Ann Arbor stage, high IPI scores, but not with efficacy after primary therapy containing PEG-Asp or L-Asp. The Kaplan-Meier analysis showed that patients with NK/T cell lymphoma who had low ASNS expression in general had a better prognosis than those with high ASNS expression. Multivariate analysis revealed that the ASNS expression level might be a significant prognostic indicator affecting survival after chemotherapy containing PEG-Asp or L-Asp. The cells that expressed low ASNS protein levels were more sensitive to L-Asp treatment probably because they produce less asparagine and are, therefore, more dependent on extracellular asparagine to meet metabolic demands. Yet, the mRNA expression level of ASNS does not necessarily correlate with protein level and enzyme activity of ASNS. However, Hutson et al (23) confirmed that the mRNA level corresponded to protein and activity levels. In a previous study, it was reported that most types of tumors, particularly leukemia and lymphoma, lack activity of ASNS (24) . Although ASNS mRNA analysis led to variable conclusions regarding the relationship between ASNS mRNA levels in primary ALL cells and L-Asp sensitivity, in the present study, we confirmed that there is some relationship between ASNS mRNA expression and the sensitivity to PEG-Asp in vitro. Moreover, recent research suggests that the expression level of ASNS in cell lines can better reflect the sensitivity to L-Asp, while in clinical specimens the results have been questionable (25) . Previous studies on pediatric ALL showed that ASNS mRNA expression was linked with L-Asp resistance only in TEL-AML1-negative but not TEL-AML1-positive ALL. TEL-AML1-positive ALL patients were more sensitive to L-Asp compared with TEL-AML1-negative patients, although the former had a relative high level of ASNS (26), and also high expression of ASNS was associated with poor prognosis compared with low expression in TEL-AML1-negative but not in TEL-AML1-positive B-lineage ALL (27) . Therefore, the ASNS level alone does not determine sensitivity to L-Asp at least in some subtypes of hematological malignancies. Thus, it is generally accepted that the role of ASNS in leukaemic cells with regard to L-Asp resistance may vary among genetic subtypes (26) (27) (28) . In the present study, we also came to the same conclusion that no correlation was found between the ASNS expression level and CR rate. This could also be due to the relatively small number of patients and the varied chemotherapy regimens except L-Asp. What is more, for NK/T cell lymphoma, we did not examine the genetic aberrations, and whether there is a potential relationship between gene fusion or other subtypes of aberrations and ASNS expression. Pancreatic and ovarian tumors and HCC with low ASNS expression levels have also been proposed for L-Asp therapy (17, 20, 29) . In addition, one study revealed that this drug has an antiproliferative effect in β-catenin-mutated HepG2 cells (30) . This result extends the findings of those from previous studies on pancreatic and ovarian tumors and HCC indicating that ASNS may be a potential therapeutic target in the treatment of NK/T cell lymphoma. Based on the severe side-effects of this drug, such as pancreatitis and allergic reactions, it is necessary to stratify patients based on the ASNS expression level in the tumor. Low expression of ASNS identified by bDNA-LCT might be an early warning sign that patients should be closely monitored and receive chemotherapy containing L-Asp or PEG-Asp. It has been proposed that NK/T cell lymphoma patients with low ASNS expression levels may benefit more from treatment with L-Asp, which can also alleviate the adverse effect and economic burden of patients with high ASNS expression.
How the ASNS gene affects prognosis is an important issue. One reason is that the expression level of ASNS has a certain relationship with the sensitivity to L-Asp. A high expression level of ASNS indicates that these patients are more likely to be resistant to chemotherapy regimens containing L-Asp or PEG-Asp. Therefore, they may not easily achieve complete remission which will affect long-term prognosis. On the other hand, Greco et al (31) and Gong and Basilico (32) determined that ASNS could complement temperature-sensitive hamster BHK ts11 cells, which are specifically blocked in progressing through the G1 phase of the cell cycle when grown at a nonpermissive temperature. This loss in ASNS activity leads to cell cycle arrest, as a consequence of a depletion of cellular asparagine, and a corresponding increase in ASNS mRNA due to regulatory mechanisms. Thus, we conclude that the ASNS gene plays a critical role in the regulation of the cell cycle. A high level of ASNS results in cell cycle dysregulation in tumors. Thus, it may have specific impact on the malignant phenotype of tumors. Accordingly it may have an effect on the prognosis of NK/T cell lymphoma patients. Activation of the GCN2-eIF2-ATF4 signaling pathway, leading to increased ASNS expression, appears to be a component of solid tumor adaptation to nutrient deprivation and/or hypoxia, so that ASNS function extends beyond asparagine biosynthesis (24) . There is also evidence suggesting that ASNS is important in certain metastatic mechanisms. When cancer spreads from the primary tumor to distant sites, cells enter into the bloodstream and exist in suspension until they reach a metastatic site. Patrikainen et al (33) and Ameri et al (34) observed that PC-3 prostate cancer cells and human MDA-MB-231 breast cancer cells which have a strong potential for distant metastasis and an increased capacity for colony formation exhibit an elevated expression of ASNS. Its increased abundance in metastasizing cells suggests that ASNS activity is beneficial for cancer cell survival once they detach from the primary tumor and enter the bloodstream. Patients with high ASNS expression are more susceptible to tumors than patients with low ASNS expression and have a tendency to develop distant metastasis thus are rendered with a malignant phenotype.
In conclusion, the present study explored the effects of ASNS on the drug sensitivity and prognosis in NK/T cell lymphoma patients for the first time. High ASNS expression is associated with a poorer performance at diagnosis and a less favorable long-term outcome. Based on these results, low ASNS expression may be used to select patients for treatment with L-Asp or PEG-Asp-containing chemotherapy regimens. In addition, an alternative therapeutic strategy for patients with low ASNS expression was also addressed.
